Who
Gina Mazzariello
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Amylyx Pharmaceuticals.
In numbers
- Trades disclosed
- 45
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $2.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Feb 2022
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $309K9,525 at $32.46 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36711 at $33.34 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $309K9,525 at $32.46 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36711 at $33.34 | filing |
| 18 Aug 2026filed 20 Aug 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —21,284 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —21,284 at $0.00 | filing |
| 10 Jul 2026filed 13 Jul 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $264K15,000 at $17.61 | filing |
| 10 Jul 2026filed 13 Jul 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $264K15,000 at $17.61 | filing |
| 9 Jul 2026filed 13 Jul 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $275K15,000 at $18.32 | filing |
| 9 Jul 2026filed 13 Jul 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $275K15,000 at $18.32 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —74,660 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,990 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,990 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —74,660 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $99K6,844 at $14.52 | filing |
| 2 Mar 2026filed 4 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $99K6,844 at $14.52 | filing |
| 23 Feb 2026filed 25 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $48K3,419 at $14.14 | filing |
| 23 Feb 2026filed 25 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $48K3,419 at $14.14 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $51K3,448 at $14.65 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $51K3,448 at $14.65 | filing |
News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $39.00AMLX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Gina Mazzariello; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.